Scholarlink

Background <p>Ureteropelvic junction obstruction (UPJO) is a leading cause of congenital hydronephrosis. Its etiology is associated with dysregulated extracellular matrix (ECM) remodeling and epithelial-mesenchymal transition (EMT). While Hepatocyte Growth Factor (HGF) is a known antagonist of fibrosis in other organs, its role in human UPJO pathogenesis remains unexplored.</p> Methods <p>Stenotic ureteropelvic junction (UPJ) tissues from pediatric UPJO patients (<i>n</i> = 40) and normal ureteral tissues from duplex kidney controls (Ctrl, <i>n</i> = 10) were obtained in our hospital. Analyses included demographic and clinical characteristics, immunohistochemistry (IHC), quantitative real-time PCR (qPCR), and Western blotting (WB) to assess HGF, fibrosis markers (Col1a1, Fibronectin 1 [FN1], α-smooth muscle actin [α-SMA]), and EMT markers (E-cadherin, N-cadherin, β-catenin, Vimentin). In vitro studies used TGFβ-stimulated human ureteral epithelial cells (SV-HUC-1) ± HGF co-treatment to evaluate fibrosis, EMT, and cell migration (scratch assay).</p> Results <p>The UPJO group was characterized by a significant male predominance, more severe hydronephrosis as evidenced by larger renal pelvic diameter and higher Society of Fetal Urology (SFU) grade, and comparable age and weight to the Ctrl group. IHC, qPCR, and WB revealed significant downregulation of HGF and the epithelial marker E-cadherin, alongside marked upregulation of fibrosis markers (Col1a1, FN1, α-SMA) and mesenchymal markers (N-cadherin, β-catenin, Vimentin) in stenotic UPJ tissues versus Ctrls. In vitro, HGF co-treatment significantly attenuated TGFβ-induced upregulation of fibrotic markers (Col1a1, FN1, α-SMA), EMT (reversal of E-cadherin downregulation and N-cadherin/β-catenin/Vimentin upregulation), and enhanced SV-HUC-1 cell migration.</p> Conclusion <p>This study provides the first clinical evidence of HGF downregulation at stenotic UPJ segments in UPJO patients, correlating with elevated fibrosis and EMT markers. These findings implicate impaired HGF signaling in UPJO pathogenesis and position HGF as a promising therapeutic target for mitigating fibrotic obstruction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hepatocyte growth factor blocks epithelial-mesenchymal transition and fibrosis of ureteral epithelial cells in UPJO

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月28日

查看全文
  • Xiaoqiang Lin,
  • Yanhui Wang,
  • Ziwei Jian,
  • Fengbin Yang,
  • Songbin Lin,
  • Weicheng Huang,
  • Yuexian Yang,
  • Shu Chen,
  • Jinrong Chen,
  • Wenyou Chen

摘要

Background

Ureteropelvic junction obstruction (UPJO) is a leading cause of congenital hydronephrosis. Its etiology is associated with dysregulated extracellular matrix (ECM) remodeling and epithelial-mesenchymal transition (EMT). While Hepatocyte Growth Factor (HGF) is a known antagonist of fibrosis in other organs, its role in human UPJO pathogenesis remains unexplored.

Methods

Stenotic ureteropelvic junction (UPJ) tissues from pediatric UPJO patients (n = 40) and normal ureteral tissues from duplex kidney controls (Ctrl, n = 10) were obtained in our hospital. Analyses included demographic and clinical characteristics, immunohistochemistry (IHC), quantitative real-time PCR (qPCR), and Western blotting (WB) to assess HGF, fibrosis markers (Col1a1, Fibronectin 1 [FN1], α-smooth muscle actin [α-SMA]), and EMT markers (E-cadherin, N-cadherin, β-catenin, Vimentin). In vitro studies used TGFβ-stimulated human ureteral epithelial cells (SV-HUC-1) ± HGF co-treatment to evaluate fibrosis, EMT, and cell migration (scratch assay).

Results

The UPJO group was characterized by a significant male predominance, more severe hydronephrosis as evidenced by larger renal pelvic diameter and higher Society of Fetal Urology (SFU) grade, and comparable age and weight to the Ctrl group. IHC, qPCR, and WB revealed significant downregulation of HGF and the epithelial marker E-cadherin, alongside marked upregulation of fibrosis markers (Col1a1, FN1, α-SMA) and mesenchymal markers (N-cadherin, β-catenin, Vimentin) in stenotic UPJ tissues versus Ctrls. In vitro, HGF co-treatment significantly attenuated TGFβ-induced upregulation of fibrotic markers (Col1a1, FN1, α-SMA), EMT (reversal of E-cadherin downregulation and N-cadherin/β-catenin/Vimentin upregulation), and enhanced SV-HUC-1 cell migration.

Conclusion

This study provides the first clinical evidence of HGF downregulation at stenotic UPJ segments in UPJO patients, correlating with elevated fibrosis and EMT markers. These findings implicate impaired HGF signaling in UPJO pathogenesis and position HGF as a promising therapeutic target for mitigating fibrotic obstruction.